Immunologic Factors: all 3,292 studies that test it

Page 5 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsActive, not recruitingNCT05222555Phase 1/2Results posted
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemActive, not recruitingNCT05211336Phase 1Results posted
• Natalizumab and Chronic InflammationTerminatedNCT05177718Phase 4Results posted
• A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT05144009Phase 2Results posted
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Active, not recruitingNCT05123703Phase 3Results posted
• MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedNCT05090566Phase 2Results posted
• Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyCompletedNCT05065970Phase 2Results posted
• Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaCompletedNCT05032820Phase 2Results posted
• A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving OcrelizumabCompletedNCT04998851Phase 4Results posted
• A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During PregnancyCompletedNCT04998812Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell LymphomaActive, not recruitingNCT04980222Phase 2Results posted
• Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple SclerosisTerminatedNCT04925557Phase 2/3Results posted
• Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.TerminatedNCT04877457Phase 4Results posted
• Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma PatientsTerminatedNCT04843579Phase 2Results posted
• An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency DiseaseCompletedNCT04842643Phase 3Results posted
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLCTerminatedNCT04786964Phase 3Results posted
• SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular LymphomaTerminatedNCT04762160Phase 2Results posted
• Sargramostim Use in COVID-19 to Recover Patient HealthCompletedNCT04707664Phase 2Results posted
• A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaTerminatedNCT04700176Phase 2Results posted
• Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04665765Phase 2Results posted
• To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingNCT04661007Phase 1/2Results posted
• A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT04660799Phase 2Results posted
• Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04659044Phase 2Results posted
• A Phase II/III Study of SargramostimCompletedNCT04642950Phase 2/3Results posted
• Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in MalawiCompletedNCT04585893Phase 2Results posted
• A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult ParticipantsCompletedNCT04578535Phase 1Results posted
• FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHLCompletedNCT04555811Phase 1Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)Active, not recruitingNCT04548999Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04544436Phase 3Results posted
• Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young AdultsTerminatedNCT04530487Phase 2Results posted
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
• Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory PneumonitisTerminatedNCT04438382Phase 2Results posted
• Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
• A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsTerminatedNCT04424641Phase 1/2Results posted
• Study of Sargramostim in Patients With COVID-19CompletedNCT04411680Phase 2Results posted
• Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19CompletedNCT04411667Phase 4Results posted
• Octagam 10% Therapy in COVID-19 Patients With Severe Disease ProgressionCompletedNCT04400058Phase 3Results posted
• Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruitingNCT04385277Phase 2Results posted
• Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)Active, not recruitingNCT04375228Phase 2Results posted
• A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)CompletedNCT04346108Phase 3Results posted
• Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderTerminatedNCT04337827Phase 2Results posted
• Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic AnemiaCompletedNCT04328727Phase 2Results posted
• A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to DaratumumabActive, not recruitingNCT04302324Phase 2Results posted
• STOP-T1D Low-Dose (ATG)TerminatedNCT04291703Phase 2Results posted
• Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple SclerosisCompletedNCT04261790Phase 4Results posted
• Ibrutinib and Rituxan for Chronic GVHDTerminatedNCT04235036Phase 2Results posted
• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletCompletedNCT04191616Phase 2Results posted
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive, not recruitingNCT04181827Phase 3Results posted
• Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
• Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)CompletedNCT04145440Phase 1/2Results posted
• Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04113018Phase 2Results posted
• A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04075266Phase 2Results posted
• A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaTerminatedNCT04074330Phase 1/2Results posted
• Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedNCT04066114Phase 1/2Results posted
• A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)CompletedNCT04062448Phase 2Results posted
• Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT04047797Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)TerminatedNCT04044690Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisActive, not recruitingNCT04035005Phase 3Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedNCT04002401Phase 2Results posted
• IVIG-eye Drops Treatment for Dry Eye DiseaseCompletedNCT03992482Phase 1/2Results posted
• Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)CompletedNCT03983018Phase 2Results posted
• Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID PatientsCompletedNCT03961009Phase 3Results posted
• Split-Dose R-CHOP for Older Adults With DLBCLActive, not recruitingNCT03943901Phase 2Results posted
• Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaCompletedNCT03934684Phase 4Results posted
• IVIG (Gamunex-C) Treatment Study for POTS SubjectsCompletedNCT03919773Phase 1/2Results posted
• Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaTerminatedNCT03919175Phase 2Results posted
• Pomalidomide for the Treatment of Bleeding in HHTCompletedNCT03910244Phase 2Results posted
• Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLActive, not recruitingNCT03863184Phase 2Results posted
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03859427Phase 3Results posted
• Short-term B-cell Depletion in Relapsing Multiple SclerosisCompletedNCT03853746Phase 4Results posted
• Efficacy of Ocrelizumab in Autoimmune EncephalitisTerminatedNCT03835728Phase 2Results posted
• Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeCompletedNCT03834688Phase 2Results posted
• An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma TreatmentsCompletedNCT03828292Phase 1Results posted
• Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaActive, not recruitingNCT03805932Phase 1Results posted
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaActive, not recruitingNCT03789240Phase 2Results posted
• Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
• Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedNCT03786783Phase 2Results posted
• Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
• Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab TherapyCompletedNCT03719131Phase 2Results posted
• Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaCompletedNCT03713294Phase 2Results posted
• Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT03702725Phase 1Results posted
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationCompletedNCT03689972Phase 3Results posted
• Ibrutinib Plus Rituximab for cGVHD Following Allo-SCTTerminatedNCT03689894Phase 1/2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationActive, not recruitingNCT03663933Phase 2Results posted
• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant RecipientsCompletedNCT03663335Phase 2Results posted
• Rituximab + Immunotherapy in Follicular LymphomaTerminatedNCT03636503Phase 1Results posted
• Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's MacroglobulinaemiaCompletedNCT03630042Phase 2Results posted
• Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaCompletedNCT03623373Phase 2Results posted
• Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaCompletedNCT03609593Phase 2Results posted
• Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionCompletedNCT03601806Phase 2Results posted
• This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)CompletedNCT03599245Phase 3Results posted
• Cardiac Safe Transplants for Systemic SclerosisTerminatedNCT03593902Phase 2/3Results posted
• A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03567616Phase 2Results posted
• To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03544281Phase 1/2Results posted
• BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
• A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's DiseaseTerminatedNCT03478956Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyCompletedNCT03416374Phase 4Results posted
• Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideTerminatedNCT03411031Phase 2Results posted
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaCompletedNCT03409432Phase 2Results posted

← Immunologic Factors overview